Royalty Pharma (RPRX) Net Cash Flow (2019 - 2026)

Royalty Pharma has reported Net Cash Flow for 8 years, with the latest figure at -$32.3 million in Q1 2026.

• Quarterly Net Cash Flow fell 120.35% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$501.3 million (down 304.86% YoY) and the FY2025 annual result came in at -$310.3 million, down 168.65% from the prior year.
• Net Cash Flow rose to -$32.3 million in Q1 2026 per RPRX's latest filing, from -$320.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $921.6 million in Q2 2024 and troughed at -$1.2 billion in Q3 2023.
• A 5-year average of -$56.2 million and a median of $158.7 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow surged 376.84% in 2022, then plunged 1423.1% in 2025.
• Over 5 years, Net Cash Flow stood at $719.1 million in 2022, then sank by 163.89% to -$459.4 million in 2023, then surged by 95.42% to -$21.0 million in 2024, then slumped by 1423.1% to -$320.2 million in 2025, then soared by 89.91% to -$32.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$32.3 million, -$320.2 million, and $307.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.